NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis

 
• By Ayisha Sharma

Emerging Company Profile: The Danish firm has achieved proof-of-mechanism for its first-in-class CIC-1 inhibitor asset in myasthenia gravis as it advances a pipeline of transformative therapies for rare neuromuscular disorders.  

Emerging Company Profile: NMD Pharma
The Chlorine Ion Channel Is Found Exclusively In Skeletal Muscle • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs